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1Transcatheter aortic valve implantation (TAVI) has rapidly evolved during the past decade and is now well established 
for the treatment of patients with severe, symptomatic steno-
sis at increased surgical risk. Results from randomized clinical 
trials reported long-term outcomes, which were comparable or 
superior to surgical aortic valve replacement (SAVR) among 
patients at intermediate to high surgical risk.1,2 Over the years, 
technological advancement in valve design and delivery, opti-
mized peri-interventional medical management, and, not least, 
improved patient selection have led to breathtaking improve-
ments in periprocedural outcomes. This development has been 
recently highlighted by the report of the 30-day results of the 
Placement of Aortic Transcatheter Valve (PARTNER) II S3 trial 
performed in high (Society of Thoracic Surgeons [STS] score, 
8.6%) and intermediate risk (mean STS score, 5.3%) patients. 
Using the Edwards Sapien 3 system (Edwards Lifesciences, 
Irvine, CA), the investigators reported exceedingly low rates 
of mortality (2.2% and 1.1% in the high- and intermediate-risk 
cohort, respectively), with an observed to estimated (STS score 
based) ratio of mortality of 0.26 in the high-risk cohort and 0.21 
in the intermediate-risk cohort. For the purpose of comparison, 
the 30-day mortality in the transcatheter group of the PARTNER 
A trial amounted to 5.2% with an observed to estimated mor-
tality ratio of 0.44.3 Notwithstanding, despite the indisputable 
benefits of TAVI, the recently published long-term data from 
the PARTNER B trial highlighted the high mortality (72%) and 
readmission rates (48%) within 5 years of follow-up among 
inoperable TAVI patients.4 Ideally, improvements in clinical 
outcomes after TAVI should go beyond a reduction in mortality 
and also address improvements in quality of life. Therefore, it 
is of pivotal importance for the Heart Team to identify patients 
and lesions who benefit most from this intervention.
See Article by Lindman et al
Several independent predictors of mortality related to 
TAVI have been established including various comorbidities 
and procedural factors. In a recent study, the analysis of the 
outcomes of >3700 TAVI patients identified moderate or 
severe aortic regurgitation (hazard ratio [HR], 2.79; 95% 
confidence interval [CI], 1.82–4.27; P<0.001), atrial fibrilla-
tion (HR, 2.33; 95% CI, 1.62–3.35; P<0.001), new-onset left 
bundle branch block (HR, 2.26; 95% CI, 1.23–4.14; P=0.009), 
chronic obstructive pulmonary disease (HR, 1.59; 95% CI, 
1.11–2.29; P=0.012), elevated systolic pulmonary artery pres-
sure (>60 mm Hg; HR, 1.99; 95% CI, 1.21–3.28; P=0.007), 
reduced left ventricular ejection fraction (<40%; HR, 1.68; 
95% CI, 1.10–2.56; P=0.017), lower mean transaortic gradi-
ent (HR, 1.11; 95% CI, 1.02–1.22; P=0.04), and transapical 
access (HR, 2.38; 95% CI, 1.60–3.54; P<0.001) as predictors 
of cardiac deaths.5
Concomitant valvular heart disease represents another prev-
alent condition that may influence the outcomes of patients 
undergoing TAVI. Pooling the data of large-scale TAVI regis-
tries, coexisting moderate to severe mitral regurgitation (MR) 
is encountered in 19% to 34% of the patients.6 Despite limited 
data, relevant tricuspid regurgitation (TR) seems equally fre-
quent, affecting 15% to 25% of patients undergoing TAVI.7,8 
In the past, both MR and TR have been associated with an 
increased risk of mortality after SAVR.9,10 More recently, 
moderate to severe MR has also been related to worse clini-
cal outcomes after TAVI,6 whereas the association is less well 
established among patients with relevant TR.7
Although the prognostic effect of left-sided heart disease 
has been well investigated, far less attention has been paid to 
the right side of the heart, in particular, right ventricular (RV) 
function and tricuspid valve regurgitation. The study published 
in this issue of Circulation: Cardiovascular Interventions by 
Lindman et al11 intends to fill this gap in our knowledge.
The PARTNER II trial was designed to compare the bal-
loon-expandable Sapien XT prosthesis with the first-genera-
tion Edwards SAPIEN bioprosthesis among 542 patients with 
severe aortic stenosis deemed inoperable. Using data from this 
study (cohort B), the authors investigated the effect of RV dys-
function and TR on prognosis and 1-year mortality. For this 
purpose, RV fractional area change and dimensions of the RV 
along with TR severity were assessed by transthoracic echo-
cardiography at baseline and analyzed by an independent core 
laboratory. In addition, invasive hemodynamic measurements 
were obtained at the time of the procedure. After multivariable 
adjustment, moderate to severe TR as well as RV and right atrial 
enlargement were found to be independently associated with 
increased 1-year mortality. However, this did not apply for RV 
dysfunction. Of note, moderate to severe TR was associated 
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with increased mortality among patients without coexisting 
MR, whereas this was not the case in patients with moderate 
to severe MR. In contrast to previous studies, increased pul-
monary artery pressure did not result in adverse prognosis. At 
1-year follow-up, TR improved from moderate-severe to trace-
mild in ≈30% of the patients, and RV dysfunction resolved in 
all patients in whom follow-up data were available.
Although these findings provide important insights into the 
poorly explored effect of right heart disease and TR, some lim-
itations inherent to the study design deserve considerations. 
First, because of the selection of high-risk patients (mean age, 
>84 years; mean STS, >10%), the results may not be appli-
cable to younger lower risk patients increasingly evaluated for 
TAVI. Second, the retrospective nature of the study may have 
been associated with imperfect echocardiographic assessment 
of MR, TR, and RV function because the initial protocol did 
not focus on the influence of multivalvular disease. Third, 
information on the frequency and intensity of medical treat-
ment, in particular diuretics, is lacking.
TAVI and TR
TR is most frequently the result of secondary causes, including 
left heart failure, concomitant MR, and pulmonary hypertension, 
eventually leading to RV volume overload with subsequent RV 
hypertrophy and enlargement. As a consequence of increased 
pericardial constraint, relative RV ischemia, and modified left 
ventricular geometry, reduction of cardiac output may occur late 
in the disease course, resulting in congestive heart failure. Vague 
echocardiographic definition, high dependence from preload 
and afterload conditions, as well as frequent association with 
interfering comorbidities render TR assessment, and the deter-
mination of its prognostic value particularly challenging.
Although the effect of isolated TR is well established,12 the 
true clinical consequences of TR after left-sided valve sur-
gery still remain a subject of controversy. Outcome studies 
focusing on the prognostic value of TR occurring late after 
surgery produced contradictory results.13,14 Only a recently 
published report investigated the effect of baseline TR and its 
evolution after SAVR. In this study, relevant TR was identi-
fied in 15% of 354 surgical patients and improvement after 
SAVR occurred in only half of the patients.10 After TAVI, TR 
improvement has been reported to occur in 15% to 50% of 
the patients. However, TR severity was not associated with 
mortality after multivariable adjustments in these studies.7,15 
Although conflicting with the results of Lindman et al,11 these 
findings challenge the widespread notion that successful treat-
ment of left-sided valve disease effectively resolves second-
ary manifestations, including TR. Thus, improvement of TR 
requires not only reversal of its primary underlying cause, 
such as pulmonary hypertension, MR, or left ventricular 
dysfunction, but also normalization of the tricuspid annular 
abnormalities. In case of long-standing disease with profound 
changes in RV geometry and pronounced leaflet tethering, this 
may no longer be possible. The same principles may apply to 
patients presenting with comorbidities invariantly associated 
with pulmonary hypertension, such as chronic obstructive pul-
monary disease and thromboembolic disease. Furthermore, 
the frequent need for permanent pacemaker insertion after 
TAVI may also act as a factor facilitating TR.16
Another important finding of this study concerns the com-
plex interaction between TR and MR. First, moderate to severe 
MR has emerged as a predictor of impaired prognosis among 
patients undergoing TAVI, and concomitant left ventricular 
dysfunction in the context of relevant MR of degenerative cause 
seems particularly harmful.17 It is conceivable that coexisting 
untreated moderate to severe MR may prevent improvement of 
TR after TAVI because of the maintenance of increased pulmo-
nary pressures. In this particular hemodynamic situation, TR is 
only a bystander and the clinical outcome is directly related to 
relevant MR. In this context, it is important to note that the prev-
alence of MR was rather high (40.1%) in the study by Barbanti 
et al,7 which may explain at least in part the lack of effect of TR 
after multivariable adjustment.7
TAVI and RV Function
Baseline impaired RV function has been linked with poor 
short-term outcome in surgical candidates.18 After SAVR, fur-
ther deterioration of RV function has been reported, most likely 
explained by the loss of the pericardial support and impaired 
myocardial blood flow during surgery.19 In contrast, previous 
studies have provided inconsistent results on the evolution of 
RV function after TAVI (ranging from no change to signifi-
cantly improved RV function),19,20 and the prognostic effect of 
RV dysfunction among TAVI patients has not been investigated 
before.
Lindman et al11 used RV fractional area change performed 
in a limited number of patients as a quantitative indicator of 
RV function. However, because of the complex geometric 
shape of the RV, accurate appreciation of its function requires 
considerable experience and sufficient image quality of the 
right cavity (present in a minority of patients). In general, 
multimodal assessment with measurement of >1 variable is 
required to reach sufficient accuracy. As an example, peak sys-
tolic velocity of the lateral tricuspid annulus obtained by tissue 
Doppler imaging has shown particularly good correlation with 
cardiac magnetic resonance imaging, which is considered the 
gold standard.21 In contrast, RV fractional area change did not 
emerge as the best-performing variable for determination of 
RV function in another comparative study.22 Because of these 
limitations, the data on RV function should be interpreted with 
caution and serve as the basis for further investigations and 
extension to RV dysfunction.
In summary, the work by Lindman et al11 provides impor-
tant information that should be carefully implemented in the 
routine evaluation of patients considered candidates for TAVI 
presenting with multivalvular disease. According to these data, 
patients with moderate or severe TR undergoing successful 
TAVI have to be considered at increased risk of morbidity 
and mortality as long as TR persists and remains untreated. 
Depending on the cause of TR, alternative treatment options, 
including surgical management and optimal medical therapy, 
addressing pulmonary hypertension should be evaluated. In 
case of coexisting MR, the risk of mortality is even higher. 
As a result, combined or staged minimal invasive treatment 
of MR needs to be taken into consideration in inoperable or 
high-risk patients deemed eligible for TAVI. A thorough diag-
nostic work-up and all therapeutic options should be carefully 
weighed by the Heart Team and guide the discussions with the 
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patient. In the near future, the already ongoing development of 
transcatheter solutions for the treatment of the native tricus-
pid valve23 may further refine therapeutic strategies for TAVI 
patients with concomitant multiple valvular heart disease.
Disclosures
Dr Windecker received research grants to the institution from Abbott, 
Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, 
Medicines Company, and St Jude and speaker fees from Astra Zeneca, 
Eli Lilly, Abbott, Biotronik, Boston Scientific, Edwards Lifesciences, 
Medtronic, Bayer, and Biosensors. Dr Praz reports no conflicts.
References
 1. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, Webb 
JG, Douglas PS, Anderson WN, Blackstone EH, Kodali SK, Makkar RR, 
Fontana GP, Kapadia S, Bavaria J, Hahn RT, Thourani VH, Babaliaros 
V, Pichard A, Herrmann HC, Brown DL, Williams M, Davidson MJ, 
Svensson LG, Akin J; PARTNER 1 Trial Investigators. 5-year outcomes 
of transcatheter aortic valve replacement or surgical aortic valve replace-
ment for high surgical risk patients with aortic stenosis (PARTNER 1): a 
randomised controlled trial [published online ahead of print March 15, 
2015]. Lancet. doi: 10.1016/S0140-6736(15)60308-7.
 2. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, 
Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, Chetcuti S, 
Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, Petrossian G, Hughes 
GC, Harrison JK, Conte J, Maini B, Mumtaz M, Chenoweth S, Oh JK; 
U.S. CoreValve Clinical Investigators. Transcatheter aortic-valve replace-
ment with a self-expanding prosthesis. N Engl J Med. 2014;370:1790–
1798. doi: 10.1056/NEJMoa1400590.
 3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu 
EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, 
Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, 
Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. 
Transcatheter versus surgical aortic-valve replacement in high-risk patients. 
N Engl J Med. 2011;364:2187–2198. doi: 10.1056/NEJMoa1103510.
 4. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, 
Webb JG, Mack MJ, Douglas PS, Thourani VH, Babaliaros VC, Herrmann 
HC, Szeto WY, Pichard AD, Williams MR, Fontana GP, Miller DC, Anderson 
WN, Smith CR, Akin JJ, Davidson MJ; PARTNER 1 Trial Investigators. 5-
year outcomes of transcatheter aortic valve replacement compared with stan-
dard treatment for patients with inoperable aortic stenosis (PARTNER 1): a 
randomised controlled trial [published online ahead of print March 15, 2015]. 
Lancet. doi: 10.1016/S0140-6736(15)60290-2.
 5. Urena M, Webb JG, Eltchaninoff H, Muñoz-García AJ, Bouleti C, 
Tamburino C, Nombela-Franco L, Nietlispach F, Moris C, Ruel M, Dager 
AE, Serra V, Cheema AN, Amat-Santos IJ, de Brito FS, Lemos PA, Abizaid 
A, Sarmento-Leite R, Ribeiro HB, Dumont E, Barbanti M, Durand E, 
Alonso Briales JH, Himbert D, Vahanian A, Immè S, Garcia E, Maisano 
F, del Valle R, Benitez LM, García del Blanco B, Gutiérrez H, Perin MA, 
Siqueira D, Bernardi G, Philippon F, Rodés-Cabau J. Late cardiac death in 
patients undergoing transcatheter aortic valve replacement: incidence and 
predictors of advanced heart failure and sudden cardiac death. J Am Coll 
Cardiol. 2015;65:437–448. doi: 10.1016/j.jacc.2014.11.027.
 6. Chakravarty T, Van Belle E, Jilaihawi H, Noheria A, Testa L, Bedogni 
F, Rück A, Barbanti M, Toggweiler S, Thomas M, Khawaja MZ, Hutter 
A, Abramowitz Y, Siegel RJ, Cheng W, Webb J, Leon MB, Makkar RR. 
Meta-analysis of the impact of mitral regurgitation on outcomes after 
transcatheter aortic valve implantation. Am J Cardiol. 2015;115:942–949. 
doi: 10.1016/j.amjcard.2015.01.022.
 7. Barbanti M, Binder RK, Dvir D, Tan J, Freeman M, Thompson CR, 
Cheung A, Wood DA, Leipsic J, Webb JG. Prevalence and impact of 
preoperative moderate/severe tricuspid regurgitation on patients undergo-
ing transcatheter aortic valve replacement. Catheter Cardiovasc Interv. 
2015;85:677–684. doi: 10.1002/ccd.25512.
 8. Bleiziffer S, Ruge H, Mazzitelli D, Schreiber C, Hutter A, Laborde JC, 
Bauernschmitt R, Lange R. Results of percutaneous and transapical trans-
catheter aortic valve implantation performed by a surgical team. Eur J 
Cardiothorac Surg. 2009;35:615–620, discussion 620. doi: 10.1016/j.
ejcts.2008.12.041.
 9. Barreiro CJ, Patel ND, Fitton TP, Williams JA, Bonde PN, Chan V, 
Alejo DE, Gott VL, Baumgartner WA. Aortic valve replacement and 
concomitant mitral valve regurgitation in the elderly: impact on survival 
and functional outcome. Circulation. 2005;112(9 suppl):I443–I447. doi: 
10.1161/CIRCULATIONAHA.104.526046.
 10. Jeong DS, Sung K, Kim WS, Lee YT, Yang JH, Jun TG, Park PW. Fate 
of functional tricuspid regurgitation in aortic stenosis after aortic valve 
replacement. J Thorac Cardiovasc Surg. 2014;148:1328–1333.e1. doi: 
10.1016/j.jtcvs.2013.10.056.
 11. Lindman BR, Maniar, HS, Jaber WA, Lerakis, S, Mack MJ, Suri RM, 
Thourani VH, Babaliaros V, Kereiakes DJ, Whisenant B, Miller DC, 
Tuzcu EM, Svensson LG, Xu K, Doshi D, Leon MB, Zajarias A. Effect 
of tricuspid regurgitation and the right heart on survival after transcath-
eter aortic valve replacement: insights from the Placement of Aortic 
Transcatheter Valves II inoperable cohort. Circ Cardiovasc Interv. 
2015;8:e002073. doi: 10.1161/CIRCINTERVENTIONS.114.002073.
 12. Topilsky Y, Nkomo VT, Vatury O, Michelena HI, Letourneau T, Suri RM, 
Pislaru S, Park S, Mahoney DW, Biner S, Enriquez-Sarano M. Clinical 
outcome of isolated tricuspid regurgitation. JACC Cardiovasc Imaging. 
2014;7:1185–1194. doi: 10.1016/j.jcmg.2014.07.018.
 13. Kammerlander AA, Marzluf BA, Graf A, Bachmann A, Kocher A, 
Bonderman D, Mascherbauer J. Right ventricular dysfunction, but not 
tricuspid regurgitation, is associated with outcome late after left heart 
valve procedure. J Am Coll Cardiol. 2014;64:2633–2642. doi: 10.1016/j.
jacc.2014.09.062.
 14. Song H, Kim MJ, Chung CH, Choo SJ, Song MG, Song JM, Kang DH, 
Lee JW, Song JK. Factors associated with development of late significant 
tricuspid regurgitation after successful left-sided valve surgery. Heart. 
2009;95:931–936. doi: 10.1136/hrt.2008.152793.
 15. Hutter A, Bleiziffer S, Richter V, Opitz A, Hettich I, Mazzitelli D, Ruge H, 
Lange R. Transcatheter aortic valve implantation in patients with concom-
itant mitral and tricuspid regurgitation. Ann Thorac Surg. 2013;95:77–84. 
doi: 10.1016/j.athoracsur.2012.08.030.
 16. Lin G, Nishimura RA, Connolly HM, Dearani JA, Sundt TM III, Hayes 
DL. Severe symptomatic tricuspid valve regurgitation due to permanent 
pacemaker or implantable cardioverter-defibrillator leads. J Am Coll 
Cardiol. 2005;45:1672–1675. doi: 10.1016/j.jacc.2005.02.037.
 17. O’Sullivan CJ, Stortecky S, Bütikofer A, Heg D, Zanchin T, Huber C, 
Pilgrim T, Praz F, Buellesfeld L, Khattab AA, Blöchlinger S, Carrel T, 
Meier B, Zbinden S, Wenaweser P, Windecker S. Impact of mitral re-
gurgitation on clinical outcomes of patients with low-ejection fraction, 
low-gradient severe aortic stenosis undergoing transcatheter aortic valve 
implantation. Circ Cardiovasc Interv. 2015;8:e001895. doi: 10.1161/
CIRCINTERVENTIONS.114.001895.
 18. Ternacle J, Berry M, Cognet T, Kloeckner M, Damy T, Monin JL, Couetil 
JP, Dubois-Rande JL, Gueret P, Lim P. Prognostic value of right ventricular 
two-dimensional global strain in patients referred for cardiac surgery. J Am 
Soc Echocardiogr. 2013;26:721–726. doi: 10.1016/j.echo.2013.03.021.
 19. Kempny A, Diller GP, Kaleschke G, Orwat S, Funke A, Schmidt R, 
Kerckhoff G, Ghezelbash F, Rukosujew A, Reinecke H, Scheld HH, 
Baumgartner H. Impact of transcatheter aortic valve implantation or 
surgical aortic valve replacement on right ventricular function. Heart. 
2012;98:1299–1304. doi: 10.1136/heartjnl-2011-301203.
 20. Forsberg LM, Tamás E, Vánky F, Nielsen NE, Engvall J, Nylander E. Left 
and right ventricular function in aortic stenosis patients 8 weeks post-
transcatheter aortic valve implantation or surgical aortic valve replace-
ment. Eur J Echocardiogr. 2011;12:603–611. doi: 10.1093/ejechocard/
jer085.
 21. Wahl A, Praz F, Schwerzmann M, Bonel H, Koestner SC, Hullin R, Schmid 
JP, Stuber T, Delacrétaz E, Hess OM, Meier B, Seiler C. Assessment of 
right ventricular systolic function: comparison between cardiac magnetic 
resonance derived ejection fraction and pulsed-wave tissue Doppler imag-
ing of the tricuspid annulus. Int J Cardiol. 2011;151:58–62. doi: 10.1016/j.
ijcard.2010.04.089.
 22. Pavlicek M, Wahl A, Rutz T, de Marchi SF, Hille R, Wustmann K, Steck 
H, Eigenmann C, Schwerzmann M, Seiler C. Right ventricular systolic 
function assessment: rank of echocardiographic methods vs. cardiac mag-
netic resonance imaging. Eur J Echocardiogr. 2011;12:871–880. doi: 
10.1093/ejechocard/jer138.
 23. Schofer J, Bijuklic K, Tiburtius C, Hansen L, Groothuis A, Hahn RT. First-
in-human transcatheter tricuspid valve repair in a patient with severely 
regurgitant tricuspid valve. J Am Coll Cardiol. 2015;65:1190–1195. doi: 
10.1016/j.jacc.2015.01.025. 
KEY WORDS: Editorials ◼ heart diseases ◼ right ventricular function ◼ 
transcatheter aortic valve replacement ◼ tricuspid regurgitation 
 at Universitaetsbibliothek Bern on February 25, 2016http://circinterventions.ahajournals.org/Downloaded from 
Fabien Praz and Stephan Windecker
Transcatheter Aortic Valve Implantation: Forgotten Side of the Heart
Effect of Right Ventricular Function and Tricuspid Regurgitation on Outcomes After
Print ISSN: 1941-7640. Online ISSN: 1941-7632 
Copyright © 2015 American Heart Association, Inc. All rights reserved.
Avenue, Dallas, TX 75231
is published by the American Heart Association, 7272 GreenvilleCirculation: Cardiovascular Interventions 
doi: 10.1161/CIRCINTERVENTIONS.115.002577
2015;8:Circ Cardiovasc Interv. 
 http://circinterventions.ahajournals.org/content/8/4/e002577
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
  
 http://circinterventions.ahajournals.org//subscriptions/
is online at: Circulation: Cardiovascular Interventions  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Answer
Permissions and Rights Question andunder Services. Further information about this process is available in the
permission is being requested is located, click Request Permissions in the middle column of the Web page
Clearance Center, not the Editorial Office. Once the online version of the published article for which 
 can be obtained via RightsLink, a service of the CopyrightCirculation: Cardiovascular Interventionsin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 at Universitaetsbibliothek Bern on February 25, 2016http://circinterventions.ahajournals.org/Downloaded from 
